Skip to main content

Neurogenic Lower Urinary Tract Dysfunction

Neurogenic lower urinary tract dysfunction (NLUTD), the preferred contemporary term for what is still clinically called neurogenic bladder, is abnormal function of the bladder, bladder neck, and external urethral sphincter resulting from disease of the central or peripheral nervous system.[1][2][3] The goal is never just continence or quality of life but preservation of renal function through detection and treatment of high-pressure storage, followed by continence restoration in a durable way, for a patient whose neurological condition may be stable, relapsing or progressive. Lesion level suggests possible patterns, but each disease population (SCI, MS, Parkinson's, spina bifida, stroke, cauda equina) has its own natural history and evaluation cadence, covered in dedicated articles linked below.

See also Autonomic Dysreflexia; population-specific articles Spinal Cord Injury, Multiple Sclerosis, Spina Bifida, Parkinson's Disease, Stroke and Dementia, and Cauda Equina Syndrome.

Epidemiology​

  • Spinal cord injury (SCI). A 2025 US statistical-center fact sheet estimates 308,620 people living with traumatic SCI (range 259,374–393,913) and approximately 18,421 new cases annually; NLUTD is common after SCI.[38][9]
  • Multiple sclerosis (MS). A 2017 US model estimated 851,749–913,925 adults with MS.[30] LUT symptoms usually begin around six years into the illness and are reported by nearly all patients after 10 years or more.[3]
  • Spina bifida (including myelomeningocele). About 1,251 babies are born with spina bifida each year in the US; bladder function is impaired in up to 96% of patients with spina bifida.[31][9]
  • Parkinson disease. >1 million people in the US have Parkinson disease; validated questionnaires have reported lower urinary tract symptoms in 27–39%, with urgency among the common symptoms.[32][33]
  • Stroke. More than 795,000 people have a stroke each year in the US; EAU reports lower urinary tract symptoms in 57–83% at one month after stroke, with 71–80% spontaneous recovery at six months.[34][9]
  • Cauda equina syndrome. Rare but a surgical emergency; produces lifetime NLUTD in most.
  • Diabetic cystopathy. This neuropathic complication can develop insidiously; reported urodynamic prevalence varies by population and definition. An earlier report found cystopathy in 43–87% of insulin-dependent patients and an average 25% of patients taking oral hypoglycemics.[35]

The reconstructive workload in NLUTD is dominated in volume by MS and stroke, but dominated in complexity by SCI and spina bifida.

Pathophysiology — The Lesion-Level Framework​

Bladder control depends on an intact loop: bladder wall afferents to the spinal cord, then the pontine micturition center (PMC), then descending spinal efferents to the bladder and sphincter. Lesion level suggests a phenotype, but incomplete, mixed and evolving lesions require clinical and urodynamic confirmation.[3][4]

Lesion levelExamplesDominant patternStorage pressureCoordination
SuprapontineStroke, Parkinson, dementia, MS with cortical involvementDetrusor overactivity (DO) without DSDUsually lowPreserved
Suprasacral spinal (above the sacral micturition circuitry)SCI above conus, MS with spinal plaques, transverse myelitisDO + detrusor–sphincter dyssynergia (DSD)May be high — assess upper-tract riskDisrupted
Sacral / infrasacral / peripheralCauda equina, sacral SCI, pelvic-surgery / radical-hysterectomy denervation, diabetic cystopathy, spina bifida (conus level)Detrusor underactivity / areflexia with variable sphincter weaknessCan be high from fibrosis / poor complianceDepends on residual detrusor and sphincter function

Diabetic cystopathy's classic description as a purely underactive bladder is an oversimplification. In a retrospective review of urodynamic traces from 182 diabetic patients, detrusor overactivity (55%) was at least as common as impaired detrusor contractility (23%) or detrusor areflexia (10%).[14] A separate urodynamic study of 84 diabetic-cystopathy cases reported overactive-bladder symptoms in 55%, detrusor overactivity in 42% and increased bladder sensation in 14%, with detrusor-overactivity prevalence independent of diabetes duration.[15]

Pediatric transverse myelitis often presents with urinary retention requiring catheterization. In the largest reported pediatric series (43 children who required CIC at presentation), intact lower-extremity reflexes and complete neurologic recovery were each associated with a return to volitional voiding, but the cumulative risk of remaining on CIC was 60% at 1 year and still 42% at 10 years — more than half of those who initially catheterized still needed CIC at 1 year.[23]

Spinal shock and its recovery​

After acute suprasacral SCI, bladder behavior evolves during spinal shock and recovery. Maintain drainage and reassess as neurological function stabilizes; a fixed 3–6-month waiting period must not delay evaluation of unsafe storage or upper-tract deterioration.[1][9] The bladder is initially areflexic because injury above the lumbosacral cord disrupts the supraspinal reflex pathway carried by myelinated Aδ afferents; a spinal micturition reflex then emerges as unmyelinated, capsaicin-sensitive C-fiber bladder afferents that do not trigger voiding in the intact state become unmasked, converting the bladder from areflexic to reflexic over the recovery period. Voiding through this reconfigured spinal reflex is often inefficient because of the detrusor–sphincter dyssynergia described above.[13]

Why upper-tract pressure is the endpoint​

DLPP >40 cmH₂O is a historical upper-tract risk marker derived from myelodysplasia: in McGuire's 42 patients, reflux was present in 15 of 22 (68%) with leak pressure above 40 cmH₂O and in none of 20 at or below it.[6] In a retrospective series of 88 adults with spinal cord pathology, a storage pressure of only ≥15 cmH₂O was associated with upper-tract damage (adjusted RR 3.9), as was compliance <12.5 mL/cmH₂O.[10] Interpret storage pressures, compliance, reflux, imaging, and renal-function trends together. Neither a single DLPP nor compliance >10–12 mL/cmH₂O is a universal treatment endpoint.[6][10]

Classification​

Multiple systems exist; three are widely used:

Madersbacher classification​

Describes detrusor and sphincter function together to distinguish storage, emptying and outlet problems; the observed functional pattern guides treatment.[3] Madersbacher's 1990 description organized treatment around prototypes defined by the combination of detrusor activity (hyperreflexive, weak or areflexive) and sphincter activity (spastic or flaccid), for example a hyperreflexive detrusor with a spastic sphincter, or a weak detrusor with a spastic sphincter managed by clean intermittent catheterization.[26]

ICS functional classification​

Based on filling-phase detrusor function and voiding-phase emptying performance. Wein's earlier functional classification (1981) separates failure to store from failure to empty and attributes each to the bladder, the outlet or both.[27]

AUA-SUFU risk stratification (2021)​

The contemporary, practical framework used in the AUA/SUFU NLUTD guideline.[1][2]

Risk tierDefinitionWorkup intensity
Low-riskAt presentation: low-upper-tract-risk neurologic diagnosis (for example, stroke, Parkinson disease, or dementia), spontaneous voiding with low PVR, stable symptoms, and no recurrent UTI or urologic complication; or reclassified from unknown risk after normal renal function and upper-tract imaging and synergic voiding on urodynamicsNo routine imaging, renal testing, or urodynamics (statements 5 and 13)
Unknown-riskInformation insufficient to classify risk (for example suprasacral lesions, which are unknown-risk until evaluated)Imaging, renal function, multichannel urodynamics (statement 6)[1]
Moderate-riskNormal and stable renal function and normal imaging, with an elevated PVR in voiding patients, neurogenic retention, or DO with incomplete emptyingScheduled surveillance (statement 14)[1]
High-riskAbnormal or unstable renal function; hydronephrosis, new renal scarring, loss of renal parenchyma, or staghorn or large stone burden on imaging; poor compliance; VUR on fluoroscopic urodynamics; or high storage pressures with DO and DSDCloser surveillance and treatment of the risk factor (statement 15)[1]

A patient is placed in the highest stratum met in any one category (Table 3 of the guideline). CIC dependence alone does not make a patient high-risk. Assign risk from the combined clinical, renal, imaging, and urodynamic findings.[1]

Clinical Presentation​

Symptoms by phase​

PhaseSymptoms
StorageUrgency, frequency, nocturia, urge incontinence (OAB-type symptoms)
VoidingHesitancy, intermittency, weak stream, incomplete emptying, retention
Post-voidPost-micturition dribble, early refilling

Red-flag findings​

  • Autonomic dysreflexia in SCI at or above T6: see Autonomic Dysreflexia.[1]
  • Persistent hydronephrosis on surveillance imaging.
  • Renal-function decline. Rising creatinine, falling eGFR.
  • Recurrent febrile UTIs. Assess for impaired emptying, stones, unsafe pressure and other causes; do not wait for a fixed count when an infection is serious.
  • New leakage in a catheter-dependent patient. Assess drainage, storage contractions, infection, stones and possible structural injury. In women who catheterize, pelvic organ prolapse has also been described as a mechanical cause, presenting as leakage between catheterizations, a feeling of bladder fullness sooner after catheterization, or the need to catheterize more often; examine for a vaginal bulge.[16]

When LUTS suggest an undiagnosed neurological disease​

Abrupt, severe or otherwise unexplained LUTS, especially with new visual symptoms, limb weakness or sensory change, gait or balance problems, falls, tremor or bradykinesia, cognitive change, altered perineal sensation, or new voiding dysregulation, can be an early feature of an undiagnosed neurological disease. An International Continence Society consensus working group recommends focused urological and neurological examination and early neurology referral when suspicion remains after common causes are excluded, rather than ordering central-nervous-system imaging directly from the LUTS clinic.[17]

Diagnosis and Evaluation (AUA/SUFU 2021)​

Initial workup for all NLUTD patients[1]​

  • Focused history. Neurologic diagnosis, prognosis, cognition, mobility, dexterity (needed for CIC), caregiver support, prior urologic interventions.
  • Physical exam. Sacral reflexes (bulbocavernosus, anal wink, cremasteric), perineal sensation, rectal tone, resting and voluntary sphincter tone.
  • Urinalysis. Assess for hematuria and other baseline abnormalities. When symptoms suggest UTI, obtain both urinalysis and urine culture.[1]
  • Post-void residual (PVR) for any patient who spontaneously voids.
  • Optional: bladder / catheterization diary, non-invasive uroflowmetry, pad test.

Risk-stratified advanced workup​

Unknown-risk patients get (statement 6, moderate recommendation, Grade C; low-risk patients do not, statement 5)[1]:

  • Upper-tract imaging. Renal ultrasound (initial); CT or MR urography when indicated.
  • Serum creatinine / eGFR. In nonweight-bearing patients with reduced muscle mass, a creatinine-based eGFR can overstate renal function: a cohort of 102 nonweight-bearing patients (mostly NLUTD) had a substantially higher creatinine-based eGFR than a cystatin-C-based eGFR (107 vs. 80 mL/min/1.73m², P<.001), and 58% of those with imaging or urinalysis evidence of renal dysfunction were reclassified to a lower eGFR category by cystatin C. Consider cystatin C or another muscle-mass-independent marker when renal function is borderline or trending down.[18]
  • Multichannel (video)urodynamics. The central test. Reports:
    • Cystometric capacity and compliance, interpreted with the pressure trace and upper-tract findings
    • Detrusor leak-point pressure (DLPP) when measurable; distinguish it from maximum storage pressure
    • Detrusor overactivity. Amplitude, coordination with sphincter
    • DSD. Simultaneous sphincter contraction on detrusor activity
    • Post-void residual and voiding pressure–flow
    • VUR (on fluoroscopy during filling)
    • Temporary urethral occlusion. In severe neurogenic sphincteric leakage that otherwise limits filling before planned outlet or continence surgery, a penile clamp in men or a Foley-balloon technique in women has been described to permit adequate filling for assessment of capacity, compliance, reflux and detrusor overactivity; this needs specialist judgment and safety monitoring, not routine use.[19]

Additional studies (selected)​

  • Renal scintigraphy (MAG3). Split function, obstruction assessment.
  • Cystoscopy. Not routine at initial evaluation (statement 8).[1] AUA/SUFU recommends it for concomitant hematuria, recurrent UTI or a suspected anatomic anomaly such as stricture or false passage , and after bowel-segment reconstruction with gross hematuria or symptomatic recurrent UTI (statement 60).[1][2]
  • EMG of pelvic floor or sphincter. When DSD suspected but ambiguous on urodynamics.

NEUROGED 2025 — shared neurological and urological care​

The EAN/EFAS/INUS guideline supports proactively asking about urinary and sexual symptoms, assessing a three-day bladder diary and PVR when relevant, and sharing care with urology for upper-tract risk, suspected structural disease or failed initial treatment.[11]

For incomplete emptying, interpret the guideline's PVR >150 mL catheterization recommendation using repeated measurements, risks, preferences and practical burden. Catheterization may be performed by a trained caregiver. PFMT requires preserved voluntary contraction. These recommendations complement the AUA risk assessment above; patients with unknown risk still need that assessment.[11]

Management — Stepwise by Goal​

For the operative options below, see the Treatment Atlas: intradetrusor onabotulinumtoxinA, sacral neuromodulation, augmentation cystoplasty, continent catheterizable channels, bladder-neck closure, and urinary diversion.

The reconstructive plan combines renal protection with patient goals, dexterity, cognition, caregiver support, and the burden of treatment:[2][9]

  1. Protect the upper tracts. Treat unsafe pressure, poor compliance, and ineffective drainage.
  2. Achieve social continence. Dry intervals that match social and functional goals.
  3. Minimize complications. UTI, stones, skin breakdown, catheter-related complications.
  4. Maximize quality of life and independence. Integrate with caregiver resources, wheelchair transfers, and long-term durability.

Emptying strategies​

StrategyUseProsCons
Clean intermittent catheterization (CIC)Preferred for patients with NLUTD when effective emptying is otherwise impossible and the regimen is feasible[2][9]Avoids continuous urethral instrumentation; supports independenceDexterity, caregiver access, leakage, infection, and treatment burden require counseling
Spontaneous voiding with timed scheduleLow-risk patients with intact coordinationMost naturalRisk of high pressures if overactive with DSD
Indwelling urethral catheterWhen CIC is not feasibleSimple; caregiver-friendlyUTI / stone risk; urethral erosion in men, bladder-neck damage in women
Suprapubic catheter (SPC)For appropriately selected NLUTD patients requiring chronic indwelling drainage, AUA/SUFU strongly recommends suprapubic over urethral catheterization (Grade C); NEUROGED also prefers the suprapubic route.[2][11]Reduced urethral trauma; easier to manage than urethralStill has UTI / stone risk; surgical insertion. EAU also advises avoiding both indwelling routes when possible and preferring silicone catheters (encrustation, latex allergy)[9]
Intraurethral valve-pump catheter (e.g., In-Flow)Selected women with hypocontractile or acontractile bladder unable or unwilling to sustain CICExternal activator opens the urethral valve to void, then closes it; completers had PVR comparable to CIC and improved incontinence-specific quality of lifeHigh early discontinuation, chiefly from discomfort or leakage (169 of 273 women withdrew in the pivotal crossover study); confirm current device availability and regulatory status separately[20]
Credé / Valsalva voidingDiscourage unless urodynamics confirms safe pressures—Raises intravesical pressure during attempted emptying and can increase outlet resistance.[9]
Triggered reflex voidingHistoric option for selected upper motor neuron lesions with low outlet resistanceCan elicit a reflex detrusor contractionHigh-pressure voiding and autonomic dysreflexia, particularly with SCI at or above T6, can occur; close urodynamic and urological surveillance is needed.[9]

EAU 2026 strongly recommends shared decision-making and thorough training in catheterization.[9] Typical practice is four to six catheterizations a day with 12–16 Fr catheters, keeping volumes below about 400–500 mL; hydrophilic catheters are associated with fewer UTIs, and UTI rates do not clearly differ between CIC and indwelling drainage.[9] NEUROGED recommends offering CIC first-line when PVR is consistently above 150 mL.[11] In one observational series, 42% of CIC users stopped within 12 months (inconvenience, leakage, infections).[9]

Pharmacologic therapy​

For storage (DO or OAB):[2][7][8]

ClassExamplesNotes
AntimuscarinicsOxybutynin, tolterodine, solifenacin, darifenacin, trospiumEAU's first-line choice for NDO (LE 1a); agents perform similarly. Intravesical oxybutynin is a strong recommendation when the oral route is poorly tolerated. Assess constipation, emptying and cognitive burden; consider switching to a β3 agonist or other therapy when cognition is affected. Parkinson disease alone is not a class contraindication.[9][11]
β3-adrenergic agonistsMirabegron, vibegronEAU 2026 reports symptom improvement with mirabegron similar to antimuscarinics in short MS and SCI studies, without significant effects on detrusor pressure or cystometric capacity. A retrospective vibegron cohort reported improved capacity and compliance; EAU strongly recommends against using β3 agonists with the intention of reducing urodynamically proven NDO. See the β3-agonist hub.[9]
CombinationAntimuscarinic + β3Evidence for additional benefit when monotherapy inadequate.
Intradetrusor onabotulinumtoxinA200 U for adult NDO (100 U for idiopathic OAB); EAU 2026 notes that 100 U may reduce new intermittent catheterization in noncatheterizing patients with MS[9]Adult NDO dosing is distinct from pediatric weight-based dosing; see the procedure page. AUA/SUFU strongly recommends it for SCI or MS patients refractory to oral therapy (statement 40, Grade A) and allows it for other neurologic causes (statement 41, conditional, Grade C), with discussion of retention risk and possible CIC before use in patients who void ; EAU strongly recommends it when antimuscarinics fail. In the phase 3 trial (416 patients with MS or SCI), 300 U gave no clinically relevant gain over 200 U, and among patients not catheterizing at baseline CIC was started in 35% at 200 U, 42% at 300 U and 10% on placebo; UTI and retention were the commonest adverse events.[12] The guideline likewise found no efficacy difference between 200 U and 300 U but a dose-dependent rise in retention and need for CIC; in the pooled MS analysis it cites, CIC was started for retention in 31.4% at 200 U, 47.1% at 300 U and 4.5% on placebo.[2] Effect lasts about nine months and repeat injections keep working; counsel about catheterization and urodynamic reassessment.[2][5][9]

For voiding or outlet:

  • α-blockers may improve voiding parameters in selected patients who spontaneously void ; EAU also reports lower outlet resistance, PVR and dysreflexia.[2][9] Routine use in CIC-dependent patients is not the AUA recommendation.[2][9]
  • External sphincterotomy or urethral-stent endoprostheses are options for refractory DSD in men who can wear a condom catheter. Sphincterotomy (12 o'clock, cold knife or laser) is irreversible and often needs repeating; stents give comparable results with shorter surgery but cost, complications and reintervention limit their use. CIC plus antimuscarinics or botulinum toxin has displaced both in most patients.[9]

Non-pharmacologic​

  • Pelvic-floor muscle training. Modest benefit in MS, post-stroke, and mild dysfunction.
  • Behavioral measures. Timed voiding, fluid management, constipation control (always check bowel program).

Surgical / device therapy​

InterventionIndicationComments
Sacral neuromodulation (SNM)Selected NLUTD with urgency, frequency, or UUIAUA/SUFU advises against offering SNM in SCI or spina bifida and allows it for selected other patients with urgency, frequency or urgency incontinence. EAU 2026 is more permissive ("consider SNM in selected neurological patients", strong; MS patients often respond, effect on urodynamic pressures unclear) and notes MRI-conditional systems remove the old imaging barrier.[2][9]
Percutaneous tibial nerve stimulation (PTNS)Refractory OAB; MS with OAB phenotypeOffice-based; less invasive than SNM. EAU rates the evidence as limited (small non-comparative or low-quality trials; home tibial stimulation improved diaries in MS).[9]
Bladder neck incision versus continence reconstructionIncision treats documented outlet obstruction; reconstruction treats outlet incompetenceOpposing goals: establish the mechanism and storage safety before choosing surgery. Reported incision patterns include a single 12 o'clock incision, incisions at 5 and 7 o'clock, or a four-quadrant pattern at 3, 6, 9 and 12 o'clock; no pattern is established as standard. Sympathetic fibers to the internal sphincter run near the 4 and 8 o'clock positions and are best avoided.[21]
Augmentation cystoplasty (including ileocystoplasty)Refractory poor compliance or high storage pressures despite medical therapy; hostile bladderAUA/SUFU: may be offered in selected patients. EAU: strong recommendation when compliance is low or NDO refractory. An EAU-cited review of adult neuro-urological bladder augmentation, without an ileocystoplasty-only estimate, reports perforation 1.9%, mucus production 12.5%, metabolic abnormalities 3.35%, bowel dysfunction 15% and stones 10%. Lifelong follow-up after bowel-segment reconstruction includes at least annual focused history, examination, symptom review, basic metabolic panel, and urinary-tract imaging ; investigate cancer warning symptoms rather than perform routine screening cystoscopy.[2][9]
Continent catheterizable channel (Mitrofanoff / Monti)CIC required but urethra inaccessible (wheelchair, prior urethral reconstruction, obese, pediatric)May be isolated or combined with augmentation according to storage needs, regardless of neurological diagnosis. In an EAU-cited review of 213 adults, 85 postoperative events required reoperation, and tube stenosis occurred in 4–32% of cases.[2][9]
Bladder-neck closureIncompetent outlet with catheter leakage; radiation bladder-neck erosionIrreversible outlet sacrifice — arrange reliable drainage through a CCC, suprapubic catheter or selected diversion.[2]
Urinary diversion (ileal conduit or continent)Refractory disease where reconstruction is not feasible (radiation, extensive fibrosis, severe dementia, prior failed reconstructions)Lifelong surveillance.
Continence surgery for neurogenic SUI (sling, AUS)Sphincter incompetence once storage pressure is controlledEAU: autologous sling first-line in women able to self-catheterize ; AUS for men and selected women (weak, experienced centers). Neurogenic AUS complication and reoperation rates run up to 60%; in a 14-man series (10 with spina bifida, four with SCI; median follow-up 18.3 years), estimated revision-free survival at 20 years was 7.1%.[9][39]

Autonomic dysreflexia prevention​

In SCI at or above T6, any urologic manipulation (cystoscopy, catheterization, urodynamics) risks autonomic dysreflexia. Prophylaxis includes topical lidocaine, gentle technique, BP monitoring, and ready access to short-acting antihypertensives. If autonomic dysreflexia develops during cystoscopy or urodynamics, stop the procedure, drain the bladder, and continue BP monitoring; initiate drug treatment or escalate care if it persists.[1] See Autonomic Dysreflexia.

Complications and Surveillance​

Upper tract​

  • Hydronephrosis. Silent until advanced; detected on surveillance imaging.
  • VUR. From high storage pressure, may require reimplantation in children; in adults, usually managed by pressure reduction.
  • Renal scarring and CKD. The historical leading cause of mortality in SCI before modern NLUTD care.
  • Urolithiasis. Bladder and upper-tract stones from stasis, infection, and prolonged catheter colonization.

Lower tract​

  • Recurrent UTI. No single numerical definition is validated across all NLUTD populations; document symptomatic, culture-supported episodes. In routine NLUTD care, asymptomatic bacteriuria (present in 23–89% of SCI patients using clean CIC) should not be screened for or treated .[1][9] Screen and treat during pregnancy and before urologic procedures with anticipated urothelial disruption or upper-tract manipulation.[1][36] NLUTD infections are complicated by definition; use culture-directed therapy for about 5–7 days, up to 14 for upper-tract or prostatic involvement.[1][9]
  • Prevention. First fix the cause: treat NDO, empty effectively, remove stones and indwelling catheters. Then consider hydrophilic catheters; for selected SCI patients on CIC with recurrent UTI, EAU 2026 strongly recommends offering weekly cycling of antibiotic prophylaxis. Drinking-water bladder irrigation may reduce catheter-associated UTI .[9] For CIC users with recurrent UTI, AUA/SUFU conditionally allows oral antimicrobial prophylaxis after discussion of resistance (statement 37, Grade C) and allows bladder instillations , without a preferred instillation agent or regimen.[2] EAU reports no demonstrated RCT benefit for cranberry or probiotics, considers methenamine ineffective, and strongly recommends avoiding continuous long-term antibiotics.[9] AUA/SUFU also recommends against daily antibiotic prophylaxis in indwelling-catheter patients (statement 30, strong, Grade B) and in CIC users without recurrent UTI (statement 31, moderate, Grade B), and finds cranberry extract not shown to reduce UTI (statement 39).[2] Do not use dipstick screening.[2][9] Bacterial interference — deliberate bladder colonization with a nonpathogenic E. coli strain — has been studied as an investigational alternative: in a multicenter randomized trial of 65 SCI patients with recurrent UTI (3:1 randomization to colonization vs. saline; 27 of 59 inoculated patients remained evaluable), UTI episodes per patient-year were fewer among colonized patients than controls (0.50 vs. 1.68).[22]
  • Urethral trauma or stricture. Especially from long-term indwelling urethral catheter in men.
  • Bladder cancer risk. Investigate hematuria or other concerning changes. AUA/SUFU strongly recommends against routine screening or surveillance cystoscopy, including in patients with chronic indwelling catheters (Grade B).[1] EAU 2026 likewise gives no validated cystoscopy interval and asks for prompt investigation of standard red flags.[9]

Systemic​

  • Autonomic dysreflexia (SCI ≥T6).
  • Sexual dysfunction and infertility. Major quality-of-life issue in SCI and MS; addressed with PDE5i, electroejaculation, IVF or ICSI as indicated.
  • Social and functional burden. Skin, caregiver, employment, transfer-equipment impact.

Surveillance cadence (2021 AUA/SUFU)[1][2]​

Risk tierHistory / exam / symptomsUpper-tract imagingRenal functionUrodynamics
Low-risk, stableReview clinical changesNot routineNot routineNot routine
Unknown-riskComplete initial assessmentBaselineBaselineBaseline, then assign risk
Moderate-risk, stableAnnualEvery 1–2 yearsAnnualClinical change
High-risk, stableAnnualAnnualAnnualRepeat as clinically indicated

EAU 2026 strongly recommends regular upper-tract assessment and baseline plus repeat urodynamics in high-risk patients, with intervals individualized by risk and treatment plan; its narrative discusses upper-tract ultrasound approximately every six months.[9] Escalate sooner for new symptoms, infection, hydronephrosis, or renal decline.[9] Do not obtain surveillance urine cultures in asymptomatic NLUTD patients during routine follow-up.[1]

Triggers for urologic assessment / escalation:[4]

  • Recurrent symptomatic UTIs or a serious or febrile episode requiring assessment; do not wait for three events
  • New or worsening hydronephrosis
  • Renal function decline
  • Stones
  • Gross hematuria
  • Urethral erosion / trauma
  • Ineffective bladder management regimen

Population-Specific Considerations (at a Glance)​

PopulationDominant patternFirst-line managementReconstructive peaks
SCI — suprasacralOften DO + DSD; assess storage pressureCIC when emptying is inadequate; antimuscarinic for NDO; onabotulinumtoxinA if oral therapy fails[2][9]Augmentation, Mitrofanoff, bladder-neck reconstruction
SCI — conus / cauda equinaAreflexia, areflexic sphincterCIC; bladder-neck support or AUSRare augmentation; AUS for ISD
Multiple sclerosisOAB, incomplete emptying; evolves with progressionAntimuscarinic / β3, CIC if retention; botulinum when refractoryRare augmentation; SNM when OAB-predominant
Parkinson diseaseOAB with preserved coordinationβ3 preferred when cognition is a concern; antimuscarinic with cognitive monitoring; botulinumRare reconstruction
Spina bifidaVariable by level; lower urinary tract dysfunction is common, and only about 12% of neonates with spinal dysraphism have no signs of neuro-urological dysfunction at birth[3][37]The 2025 EAU/ESPU-led spinal-dysraphism guideline strongly recommends CIC soon after birth, with close monitoring if it is delayed in a newborn with a clearly underactive sphincter and no detrusor overactivity.[37] SBA recommends CIC when baseline findings indicate a need.[28] Use antimuscarinic therapy for urodynamically confirmed DO and maintain a bowel program.[28][29]Augmentation + Mitrofanoff + BN procedure most commonly
Stroke / dementiaOAB ± functional incontinenceCaregiver-directed toileting, β3, incontinence padsRarely operative — focus on caregiver burden
Adult cerebral palsyVariable — DO, DSD, or a large flaccid bladder; neurologic deficits may not otherwise be prominentFull urologic evaluation of any symptomatic adult; treat per the urodynamic pattern foundRare — individualized

Adults with cerebral palsy and voiding dysfunction can have important storage or emptying abnormalities that are easy to miss without a full workup. In a urodynamic cohort of 49 symptomatic adults with moderate-to-severe CP, detrusor overactivity was found in 30%, detrusor-sphincter dyssynergia in 12%, and DLPP above 40 cmH₂O in 51% (median compliance 18 mL/cmH₂O, range 0.78–365).[24] A systematic review across children and adults with CP links upper-tract deterioration particularly to the combination of urinary symptoms and pelvic-floor spasticity.[25]

See population-specific articles (linked above) for full detail.

Clinical Correlations for the Reconstructive Urologist​

  • Hostile bladder in SCI or spina bifida: augmentation cystoplasty. Objective workup before: urodynamics documenting poor compliance or sustained high pressures, upper-tract imaging and failure or intolerance of appropriate less-invasive therapy. Established hydronephrosis is not required before treating refractory unsafe storage. Plan lifelong emptying support, stone surveillance, metabolic testing and prompt investigation of hematuria, unexplained recurrent UTI or new pain; asymptomatic screening cystoscopy is not routine.[2]
  • Mitrofanoff or Monti channel. For wheelchair-bound patients, obese patients, post-radical-pelvic-surgery patients, and many spina bifida patients, a catheterizable umbilical channel is the difference between CIC independence and caregiver dependence.
  • Bladder-neck closure is irreversible. Confirm safe storage and reliable alternative drainage; selected patients use a catheterizable channel, permanent suprapubic catheter or diversion.[2]
  • Urinary diversion as salvage. In patients with failed reconstructions, severe cognitive impairment, refractory radiation injury, or where independence is no longer the goal, an ileal conduit can dramatically simplify care.
  • Pregnancy in NLUTD. Requires a multidisciplinary plan: catheter mechanics change with the gravid uterus, UTI risk rises, surveillance tightens, and mode of delivery is coordinated with obstetrics given augmentation or Mitrofanoff anatomy.
  • Neuro-urologic care is longitudinal. Lifelong follow-up for NLUTD is risk-stratified: moderate- and high-risk patients require scheduled renal and upper-tract surveillance, while stable low-risk patients can be followed in primary care and reassessed for new symptoms or complications. Give primary-care clinicians explicit referral triggers (see above).[1][2][9]

See Also​

Podcasts​

Diagnosis & Management of Neurogenic Bladder
BackTable Urology, Ep. 335 (2026) · Benjamin Brucker, Anjali Kapur
backtable.com
SUFU22: Neurogenic Urinary Tract Dysfunction Risk Stratification
SUFU Podcast (2022)
podcasts.apple.com

Videos​

Reconstruction in Neurogenic Bladder
PedsUroFLO Lecture (2020)

References​

1. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation." J Urol. 2021;206(5):1097–1105. doi:10.1097/JU.0000000000002235

2. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-Up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

3. Panicker JN, Fowler CJ, Kessler TM. "Lower Urinary Tract Dysfunction in the Neurological Patient: Clinical Assessment and Management." Lancet Neurol. 2015;14(7):720–732. doi:10.1016/S1474-4422(15)00070-8

4. Milligan J, Goetz LL, Kennelly MJ. "A Primary Care Provider's Guide to Management of Neurogenic Lower Urinary Tract Dysfunction and Urinary Tract Infection After Spinal Cord Injury." Top Spinal Cord Inj Rehabil. 2020;26(2):108–115. doi:10.46292/sci2602-108

5. Romo PGB, Smith CP, Cox A, et al. "Non-Surgical Urologic Management of Neurogenic Bladder After Spinal Cord Injury." World J Urol. 2018;36(10):1555–1568. doi:10.1007/s00345-018-2419-z

6. McGuire EJ, Woodside JR, Borden TA, Weiss RM. "Prognostic Value of Urodynamic Testing in Myelodysplastic Patients." J Urol. 1981;126(2):205–209. doi:10.1016/S0022-5347(17)54449-3

7. Diamond DA, Chan IHY, Holland AJA, et al. "Advances in Paediatric Urology." Lancet. 2017;390(10099):1061–1071. doi:10.1016/S0140-6736(17)32282-1

8. Cameron AP. "Medical Management of Neurogenic Bladder With Oral Therapy." Transl Androl Urol. 2016;5(1):51–62. doi:10.3978/j.issn.2223-4683.2015.12.07

9. European Association of Urology. EAU Guidelines on Neuro-Urology. 2026. Sections 3.3, 3.4, and 3.7. Official guideline; 2026 changes.

10. Swatesutipun V, Tangpaitoon T. "The safety cutoff storage pressure for preventing upper urinary tract damage in neurogenic bladder from spinal cord pathology and risk factor analysis." Neurourol Urodyn. 2022;41(4). doi:10.1002/nau.24911

11. Panicker JN, Fanciulli A, Skoric MK, et al. European Academy of Neurology/European Federation of Autonomic Societies/International Neuro-Urology Society Guidelines for Practising Neurologists on the Assessment and Treatment of Neurogenic Urinary and Sexual Symptoms (NEUROGED Guidelines). Eur J Neurol. 2025. doi:10.1111/ene.70119. Full text.

12. Ginsberg D, Gousse A, Keppenne V, et al. "Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity." J Urol. 2012;187(6):2131-2139. doi:10.1016/j.juro.2012.01.125

13. de Groat WC, Yoshimura N. "Changes in afferent activity after spinal cord injury." Neurourol Urodyn. 2010;29(1):63-76. doi:10.1002/nau.20761

14. Kaplan SA, Te AE, Blaivas JG. "Urodynamic Findings in Patients with Diabetic Cystopathy." J Urol. 1995;153(2):342–344. doi:10.1097/00005392-199502000-00013

15. Yamaguchi C, Sakakibara R, Uchiyama T, et al. "Overactive Bladder in Diabetes: A Peripheral or Central Mechanism?" Neurourol Urodyn. 2007;26(6):807–813. doi:10.1002/nau.20404

16. Hartman C, Firoozi F. BPH and Pelvic Organ Prolapse in Patients with Neurogenic Bladder. In: Wood HM, Wood D, eds. Transition and Lifelong Care in Congenital Urology. Springer; 2015:131–139. doi:10.1007/978-3-319-14042-1_12

17. Roy HA, Nettleton J, Blain C, et al. "Assessment of Patients with Lower Urinary Tract Symptoms Where an Undiagnosed Neurological Disease Is Suspected: A Report from an International Continence Society Consensus Working Group." Neurourol Urodyn. 2020;39(8):2535–2543. doi:10.1002/nau.24469

18. Werneburg GT, Hettel D, Jeong S, et al. "Estimated Glomerular Filtration Rate Using Cystatin C Is a More Sensitive Marker for Kidney Dysfunction in Nonweight-Bearing Individuals." J Urol. 2023;209(2):391–398. doi:10.1097/JU.0000000000003070

19. Drake M, Nettleton J, Belal M. Neurological Disease and LUTS. In: Drake M, Hashim H, Gammie A, eds. Abrams' Urodynamics. 4th ed. Wiley-Blackwell; 2021:313–359. doi:10.1002/9781119245957.ch16

20. Chen TY, Ponsot Y, Carmel M, et al. "Multi-Centre Study of Intraurethral Valve-Pump Catheter in Women with a Hypocontractile or Acontractile Bladder." Eur Urol. 2005;48(4):628–633. doi:10.1016/j.eururo.2005.04.020

21. King AB, Goldman HB. "Bladder Outlet Obstruction in Women: Functional Causes." Curr Urol Rep. 2014;15(9):436. doi:10.1007/s11934-014-0436-z

22. Darouiche RO, Green BG, Donovan WH, et al. "Multicenter Randomized Controlled Trial of Bacterial Interference for Prevention of Urinary Tract Infection in Patients with Neurogenic Bladder." Urology. 2011;78(2):341–346. doi:10.1016/j.urology.2011.03.062

23. Hannallah A, Passoni N, Peters CA, et al. "Bladder management in children with transverse myelitis." J Pediatr Urol. 2021;17(4):522.e1-522.e6. doi:10.1016/j.jpurol.2021.04.003

24. Cotter KJ, Levy ME, Goldfarb RA, et al. "Urodynamic Findings in Adults With Moderate to Severe Cerebral Palsy." Urology. 2016;95:216-21. doi:10.1016/j.urology.2016.05.024

25. Samijn B, Van Laecke E, Renson C, et al. "Lower urinary tract symptoms and urodynamic findings in children and adults with cerebral palsy: A systematic review." Neurourol Urodyn. 2017;36(3):541-549. doi:10.1002/nau.22982

26. Madersbacher H. "The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts." Paraplegia. 1990;28(4):217-229. doi:10.1038/sc.1990.28

27. Wein AJ. "Classification of neurogenic voiding dysfunction." J Urol. 1981;125(5):605-609. doi:10.1016/s0022-5347(17)55134-4

28. Spina Bifida Association. "Urology Guideline." Guidelines for the Care of People with Spina Bifida. May 2023. Official guideline.

29. Stein R, Bogaert G, Dogan HS, et al. "EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment." Neurourol Urodyn. 2020;39(1):45-57. doi:10.1002/nau.24211

30. Wallin MT, et al. "The prevalence of MS in the United States: A population-based estimate using health claims data." Neurology. 2019;92(10):e1029–e1040. doi:10.1212/WNL.0000000000007035

31. Centers for Disease Control and Prevention. "Data and Statistics." Spina Bifida. Reviewed September 10, 2026. CDC.

32. Parkinson’s Foundation. "Parkinson’s Foundation Launches ‘Find Real Answers’ Campaign for Parkinson’s Awareness Month this April." March 31, 2026. Parkinson’s Foundation.

33. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. "Prevalence of bladder dysfunction in Parkinsons disease." Neurourol Urodyn. 2006;25(2):116–122. doi:10.1002/nau.20193.

34. Centers for Disease Control and Prevention. "Stroke Facts." October 24, 2024. CDC.

35. Frimodt-Møller C. "Diabetic cystopathy: epidemiology and related disorders." Ann Intern Med. 1980;92(2 Pt 2):318–321. doi:10.7326/0003-4819-92-2-318.

36. Nicolle LE, Gupta K, Bradley SF, et al. "Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America." Clin Infect Dis. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121

37. European Association of Urology, European Society for Paediatric Urology, et al. Guidelines on Spinal Dysraphism in Children and Adolescents. January 2025. Official guideline.

38. National Spinal Cord Injury Statistical Center. Traumatic Spinal Cord Injury Facts and Figures at a Glance: 2025 SCI Data Sheet. University of Alabama at Birmingham; 2025. Official data sheet.

39. Guillot-Tantay C, Chartier-Kastler E, Mozer P, et al. "[Male neurogenic stress urinary incontinence treated by artificial urinary sphincter AMS 800 (Boston Scientific, Boston, USA): Very long-term results (>25 years)]." Prog Urol. 2018;28(1):39–47. doi:10.1016/j.purol.2017.09.012